top of page

IRA forcing pharmas to leave cancer patients in the lurch, CEOs say

The IRA is leading pharmas to forego fast-to-patient development strategies in favor of getting onto the market first with the largest indications, the CEOs of Novartis and Genentech said Friday. Patients with smaller indications, such as mesothelioma and ovarian cancer, may have to wait years because the companies will prioritize launches of small molecules in larger indications such as lung and prostate cancer, they said...


bottom of page